

NEWS RELEASE

Collectis stem cells today announces the release of a new and improved user friendly format of stem cell derived cardiomyocytes

Gothenburg, Sweden, September 24th, 2012 – Collectis stem cells, a Business Unit of Collectis Group (Alternext: ALCLS), a premier provider of stem cell derived products and technologies, today announces the release of a new, flexible, and user friendly format of stem cell derived cardiomyocyte product, hES-CMC™.

The hES-CMC™ are highly representative of human cardiomyocytes and demonstrate a long life span with maintained functionality, making them the ideal platform for various *in vitro* applications including drug discovery and toxicity testing.

« Due to their high relevance in various industrial applications the hES-CMC™ represent a really promising system for research and development », said Mathieu Simon, CEO of Collectis stem cells. « The pharmaceutical industry has a great need for more clinically relevant models early in the drug development process to better predict cardiovascular risk and find new drug targets. We are excited to be able to provide these cells in a convenient format to our customers and partners. »

« In a short time, this is yet another confirmation of the Collectis' strategy to become the global market leader for stem cell based *in vitro* models and related technologies. We have considerably accelerated our developments in this field » said André Choulika, Chairman and CEO of Collectis Group.

About Collectis stem cells

Collectis stem cells is a business unit within the Collectis Group and is a global leader in stem cell technology. Collectis stem cells, created in November 2011 from Cellartis AB and Ectycell S.A., possesses broad expertise in pluripotent stem cells, genetic engineering and specialised cells. Collectis stem cells is developing stem cell derived products and related services for drug discovery, toxicity testing and regenerative medicine applications.

For more information please visit www.cellartis.com and www.collectis.com

About Collectis

Collectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, biological research and agriculture. Collectis is listed on the NYSE-Euronext Paris Alternext market (code: ALCLS).

To find out more, please visit www.collectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Collectis in any country.

This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

For further information, please contact:

Collectis
Mathieu Simon
Senior Vice President
Tel: +33 (0)1 81 69 16 00
media@collectis.com

Collectis
Philippe Valachs
Company Secretary
Tel: +33 (0)1 81 69 16 00
media@collectis.com

Collectis stem cells
Johan Hyllner
Chief Scientific Officer
Tel : +46 (0)31 758 0911
media@collectis.com